APG273 / AbbVie - LARVOL DELTA

AbbVie Completes Acquisition of Apogee Therapeutics (AbbVie Press Release) - "Under the terms of the agreement, Apogee shareholders received $135.11 per share in cash, for a total equity value of approximately $10.9 billion....Apogee's lead asset, zumilokibart, is a late-stage, half-life extended monoclonal antibody targeting IL-13, in development for patients with atopic dermatitis. Apogee's pipeline also includes APG273, a potential best-in-category long-acting combination targeting IL-13 and thymic stromal lymphopoietin (TSLP), in development for asthma."

M&A • Asthma • Atopic Dermatitis

Combination pipeline continues to advance across AD and respiratory conditions for APG279 and APG273 with potential for improved efficacy and dosing (GlobeNewswire) - "The Phase 1b head-to-head study evaluating APG279 (zumilokibart + APG990) versus DUPIXENT in atopic dermatitis is ongoing, with interim data expected in 2H 2026. APG273 (zumilokibart + APG333), a long-acting IL-13/TSLP combination, continues to represent a differentiated respiratory program supported by positive Phase 1 data for APG333, with additional plans to be announced in 2H 2026."

Clinical • P1 data • Atopic Dermatitis • Respiratory Diseases

AbbVie to Acquire Apogee Therapeutics for $10.9B, Adds late‑stage IL‑13 asset Zumilokibart (TradingView) - "Deal adds zumilokibart (APG777), a half‑life extended anti‑IL‑13 with positive Phase 2 AD data and Q12W–Q24W dosing potential; Apogee pipeline includes APG273 (zumilokibart + APG333) targeting asthma; transaction expands AbbVie’s dermatology and respiratory footprint; Transaction expected to close in Q3 2026 subject to regulatory and Apogee shareholder approval; accretive to adjusted diluted EPS beginning in 2032."

M&A • Asthma • Atopic Dermatitis • Chronic Obstructive Pulmonary Disease • Immunology

Combination pipeline continues to advance across AD and respiratory indications for APG279 and APG273 with potential for improved efficacy and dosing (GlobeNewswire) - "(i) Phase 1b head-to-head study of APG279 (zumilokibart + APG990) versus DUPIXENT in AD is fully enrolled and expanded to 86 patients, with interim 24-week data expected in 2H 2026; (ii) Plans to advance APG273 (zumilokibart + APG333) in respiratory indications expected to be disclosed later this year."

Enrollment closed • P1 data • Pipeline update • Atopic Dermatitis • Respiratory Diseases

Plans to advance APG273 (zumilokibart + APG333) in respiratory indications will be disclosed in 2026 (GlobeNewswire)

Clinical • Asthma • Chronic Obstructive Pulmonary Disease

Apogee Therapeutics Provides Pipeline Progress and Reports Second Quarter 2025 Financial Results (GlobeNewswire) - "A Phase 1 trial of APG333 in healthy volunteers is underway, with data expected in the fourth quarter of 2025....Apogee expects to announce plans for its combination approach of APG777 + APG333 in respiratory conditions."

New trial • P1 data • Chronic Obstructive Pulmonary Disease

The Combination of APG777 (anti-IL-13) and APG333 (anti-TSLP) Inhibits Central and Local Drivers of Obstructive Airway Disease (ATS 2025) - "Benchmark mAbs dupilumab (anti-IL-4Rα), lebrikizumab (anti-IL-13), and tezepelumab (anti-TSLP) were produced based on publicly available sequences. Consistent with TSLP and IL-13 having distinct roles in mediating obstructive airway disease pathology, administration of APG777+APG333 provided potent and broad inhibition of biomarkers of central inflammation and local airway response in primary human cells. Effects were greater and broader than those observed with benchmarks, suggesting that targeting orthogonal drivers of obstructive airway disease is a promising approach for the treatment of Th2-driven respiratory diseases. These data support the continued development of APG777+APG333 for Th2-driven inflammatory diseases."

Chronic Obstructive Pulmonary Disease • Immunology • Inflammation • Respiratory Diseases • CCL11 • CD4 • CRLF2 • IL13 • IL5 • IL6 • POSTN